Tuesday, April 27, 2010

Could Bristol-Myers' Growth Flatline Post-Plavix?

In 2009, Bristol-Myers Squibb (BMY-$24.50) derived almost one-third of its total sales, or $6.1 billion, from the blood-clot inhibitor Plavix (clopidogrel), co-marketed with French drug maker Sanofi-Aventis (SNY). Can growth from existing drugs help mitigate revenue and earnings lost to generic copycats when the drug maker's best-selling cardiovascular drug loses market exclusivity come 2012? Read More >….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

No comments: